The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML),
Posted 04 September 2012 - 04:58 PM
It will be most like Sprycel since it inhibits the SRC kinases as well as BCR-ABL, along with other off-target kinases. Pleural effusion will be an issue. There was early hope that Bosutinib would have a much better side effects profile, but that has not been demonstrated in the clinical trials. But as with all CML drugs, it is different, so the side effects will be different. The best thing is that it provides one more option for overcoming some forms of drug resistance and allows trading of side effects. It does NOT work against T315i.
Posted 05 September 2012 - 04:52 AM
Great news, approval of a new drug to help fight our disease.
Any information on when it will be approved in Europe?
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users